Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin(GlaxoSmithKline (United States)), Barry R. Keith(GlaxoSmithKline (United States)), Lei-Hua Liu(GlaxoSmithKline (United States)), Hong Ma(GlaxoSmithKline (United States)), David W. Rusnak(Research Triangle Park Foundation), Gary Owens(Research Triangle Park Foundation), Krystal J. Alligood(GlaxoSmithKline (United States)), Neil L. Spector(Research Triangle Park Foundation)
Oncogene
September 12, 2002
Cited by 669

Abstract


Related Papers

No related papers found

Powered by citation graph analysis